Hemophilia B: New Drugs
- 21 April 2022
- book chapter
- Published by Springer Nature
- p. 61-65
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Half-life extension technologies for haemostatic agentsThrombosis and Haemostasis, 2015
- Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trialBlood, 2014
- Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia BNew England Journal of Medicine, 2013
- PROLONG-9FP clinical development program – phase I results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP)Thrombosis Research, 2013
- Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9‐GP), a glycoPEGylated recombinant factor IXJournal of Thrombosis and Haemostasis, 2012
- Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patientsBlood, 2012
- Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia BBlood, 2011
- Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptideBlood, 2011
- Prolonged activity of factor IX as a monomeric Fc fusion proteinBlood, 2010
- Genetic fusion to albumin improves the pharmacokinetic properties of factor IXThrombosis and Haemostasis, 2009